Immunotherapy plus chemo before surgery for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage triple-negative breast cancer (the tumor is larger than 2 cm and has not spread to other organs).
- You are between 18 and 75 years old and in generally good health (able to do everyday activities).
- You have a known PD-L1 status (a test result for a protein that helps guide immunotherapy).
- You agree to have breast cancer surgery after the initial treatment (neoadjuvant therapy).
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control during and for 12 months after treatment.
- You have not had other cancers in the last 3 years (some early-stage or cured cancers may be allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new drug called QL1706 combined with chemotherapy given before surgery for people with early-stage, high-risk breast cancer that is estrogen receptor positive (ER+) and HER2 negative. The goal is to see if this combination can shrink tumors more effectively before surgery.
This trial tests a new drug (QL1706) combined with hormone therapy for breast cancer that did not shrink enough with initial chemotherapy. The goal is to see if this combination can improve treatment response before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.